X

NSCLC

NSCLC

Efficacy and Safety of MIL60 Compared With Bevacizumab in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer

Researchers compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients with NSCLC in this phase 3, randomized, double-blind study.

EClinicalMedicine
11/19/2021
Adjuvant Gefitinib No Better Than Chemo for NSCLC With EGFR Mutations

Adjuvant gefitinib did not prolong survival, compared with cisplatin plus vinorelbine, in patients with EGFR-mutated NSCLC, according to new phase 3 clinical trial results. 

Cancer Therapy Advisor
11/15/2021
Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non–Small-Cell Lung Cancer

Researchers observe treatment patterns of patients with aNSCLC by genomic ancestry and EHR-reported race and/or ethnicity and evaluate differences in TMB, CIT access, and treatment outcomes...

JCO Global Oncology
11/09/2021

Nivolumab-Chemotherapy Combination Extends EFS in Resectable NSCLC

Adding nivolumab to neoadjuvant chemotherapy significantly improves EFS among patients with resectable NSCLC, according to topline data released by the agent’s manufacturer.

Healio
11/08/2021
Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II–III Non-Small-Cell Lung Cancer With Distinct Adjuvant Therapy Outcomes

The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA NSCLC. 

Nature Communications
11/08/2021
Yield of Tumor Samples With a Large Guide-Sheath in Endobronchial Ultrasound Transbronchial Biopsy for Non-Small Cell Lung Cancer

Researchers investigate the utility of a large GS kit to obtain many tumor cells in patients with NSCLC.

PLOS ONE
10/29/2021
Periostin Secreted by Activated Fibroblasts in Idiopathic Pulmonary Fibrosis Promotes Tumorigenesis of Non-Small Cell Lung Cancer

The effects of periostin secreted by fibroblasts derived from IPF lung on NSCLC cell proliferation were explored and researchers propose a possible new therapeutic strategy targeting periostin...

Scientific Reports
10/26/2021
Ferroptosis-Related Gene AKR1C1 Predicts the Prognosis of Non-Small Cell Lung Cancer

The transcriptome dataset and corresponding clinical dataset from TCGA were merged with the ferroptosis-related genes for systematically bioinformatic analysis to identify DEGs from these datasets.

Cancer Cell International
10/26/2021
Quantification of the Spatial Distribution of Primary Tumors in the Lung to Develop New Prognostic Biomarkers for Locally Advanced NSCLC

This two fold study identifies areas in maps with statistically significant DSA to examine differences in outcomes between surgical or RCT regimens & quantifies the spatial distribution...

Scientific Reports
10/22/2021
Phase 2 Trial of Neoadjuvant Toripalimab With Chemotherapy for Resectable Stage III Non-Small-Cell Lung Cancer

Scientists investigate the application value and safety of the neoadjuvant toripalimab plus platinum-based doublet chemotherapy in stage III Asian NSCLC patients.

OncoImmunology
10/25/2021
Study Finds Medicaid Expansion May Be Associated With Decrease in Early Lung Cancer Mortality

The National Cancer Database is used to analyze nearly 12,000 patients over 10 years to find a decrease in early mortality following hospital discharge after surgery for NSCLC... 

The ASCO Post
10/25/2021
Clinical and Molecular Feature-Based Nomogram Model for Predicting Benefit From Bevacizumab Combined with First-Generation EGFR-TKI in EGFR-Mutant Advanced NSCLC

Scientists investigate factors affecting the efficacy of first-gen EGFR-TKI with or without bevacizumab and identify the subset of patients who can benefit from combination therapy.

BMC Medicine
10/19/2021
Prospective Observational Study of Nutritional/Immunologic Indices as Predictive Biomarkers for the Response to Anti-PD-1 Drugs in NSCLC

This study investigates the clinical impact of pre-treatment nutritional/immunologic indices and early post-treatment changes in the indices on treatment outcomes in advanced NSCLC. 

PLOS ONE
10/22/2021
GOLPH3/CKAP4 Promotes Metastasis and Tumorigenicity by Enhancing the Secretion of Exosomal WNT3A in Non-Small-Cell Lung Cancer

This research showed that GOLPH3 interacts with CKAP4 to enhance the secretion of exosomal WNT3A, leading to a stem cell-like phenotype and metastasis in NSCLC.

Cell Death & Disease
10/21/2021
Schizandrin A Can Inhibit Non‑Small Cell Lung Cancer Cell Proliferation by Inducing Cell Cycle Arrest, Apoptosis and Autophagy

Research suggests that SchA exerted inhibitory effects on NSCLC physiology by inducing cell cycle arrest and apoptosis and partially induces autophagy.

International Journal of Molecular Medicine
10/12/2021
Sintilimab Extends PFS for Certain Patients With NSCLC

 After first interim analysis, a statistically significant PFS benefit with sintilimab, bevacizumab biosimilar injection and chemotherapy was shown in the the ORIENT-31 study. 

Healio
10/18/2021
Second-Line Sotorasib Plus Afatinib for KRAS–Mutant NSCLC

Combination KRAS inhibitor sotorasib with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating patients with NSCLC and mutated KRAS...

The ASCO Post
10/18/2021
Major Pulmonary Resection After Neoadjuvant Chemotherapy or Chemoradiation in Potentially Resectable Stage III Non-Small Cell Lung Carcinoma

Research identifies predictors of postoperative outcome and survival of locally advanced NSCLC resections after neoadjuvant chemotherapy or chemoradiation.

Scientific Reports
10/12/2021
The Adaptive Responses in Non-Small Cell Lung Cancer A549 Cell Lines Induced by Low-Dose Ionizing Radiation and the Variations of miRNA Expression

Researchers detected the effects of LDR on apoptosis and cell cycle in lung cancer A549 cell line and screened the relative miRNAs using small RNA sequencing.

Dose Response
10/12/2021
CDK14 Expression is Elevated in Patients With Non-Small Cell Lung Cancer and Correlated With Poor Prognosis

Scientists investigate the clinical significance of cyclin-dependent kinase 14 expression in patients with NSCLC.

Journal of International Medical Research
10/12/2021
Identification and Validation of Tissue or ctDNA PTPRD Phosphatase Domain Deleterious Mutations as Prognostic and Predictive Biomarkers for Immune Checkpoint Inhibitors in Non-Squamous NSCLC

Scientists report that the tissue and ctDNA PTPRD phosphatase domain mutations functioned as a prognostic biomarker predicting higher ORR and favorable PFS of ICIs.

BMC Medicine
10/08/2021
Ensartinib Shows Superior Efficacy to Crizotinib in Advanced ALK-Positive NSCLC

The eXalt3 trial has shown significantly prolonged progression-free survival with ensartinib vs crizotinib in patients with advanced, recurrent, or metastatic ALK-positive NSCLC...

The ASCO Post
10/10/2021
Utility of Comprehensive Genomic Profiling in Directing Treatment and Improving Patient Outcomes in Advanced Non-Small Cell Lung Cancer

Researchers provide a re-evaluation on the clinical implications of comprehensive genomic profiling in the current treatment landscape of advanced NSCLC.

BMC Medicine
10/01/2021
Poziotinib, a Tyrosine Kinase Inhibitor, for HER2 Exon 20–Mutant NSCLC

Scientists explore poziotinib, an irreversible covalent tyrosine kinase inhibitor thats smaller size and greater flexibility may allow the drug to circumvent steric hindrance...

The ASCO Post
09/29/2021
CALR-TLR4 Complex Inhibits Non-Small Cell Lung Cancer Progression by Regulating the Migration and Maturation of Dendritic Cells

Research showed that mCALR expression was positively correlated with DC infiltration in NSCLC tissues.

Frontiers in Oncology
10/01/2021
Do Endocrine Adverse Events Predict Longer Progression-Free Survival Among Patients with Non-Small-Cell Lung Cancer Receiving Nivolumab?

The aim of the study was to assess the occurrence and nature of immune-related endocrine adverse events (irAEs) among patients with non-small-cell lung cancer (NSCLC) treated with nivolumab.

PLOS ONE
09/29/2021
Development of a Novel ALK Rearrangement Screening Test for NSCLC

This study aims to overcome the obstacles of ALK fusion gene detection by RT-PCR in the context of suboptimal RNA quality and unknown fusion partners of ALK.

PLOS ONE
09/24/2021
Development of a Novel ALK Rearrangement Screening Test for Non–Small-Cell Lung Cancers

A novel RNA-based ALK KD analysis was developed for ALK rearrangement screening in MPE and FFPE specimens of NSCLC.

PLOS ONE
09/26/2021
Sugemalimab Deemed Effective as Consolidation for Stage III Non–Small-Cell Lung Cancer

Consolidation with sugemalimab improves PFS, compared with placebo, in patients with unresectable, stage III NSCLC who have not progressed after CRT, phase 3 results suggest.

Cancer Therapy Advisor
09/19/2021
Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non–Small-Cell Lung Cancer

The aim of this study was to determine whether the protein CDCA3 might be a biomarker for TKI response in EGFR mutant lung cancer. 

Cancers
09/16/2021
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer

This phase III study investigates the efficacy and safety of poly (ADP-ribose) polymerase inhibitor veliparib in combination with conventional chemotherapy for advanced sqNSCLC.

Journal of Clinical Oncology
08/26/2021
Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer

Study investigators report the final results of a phase I study of osimertinib and dasatinib in TKI-naïve patients with EGFR-mutated NSCLC.

Frontiers in Oncology
09/08/2021
Prognostic Model of Long-Term Advanced Stage (IIIB-IV) EGFR Mutated NSCLC Survivors Using Real-Life Data

This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months.

BMC Cancer
08/31/2021

source list reference

rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
#cc529a
#c59445
#c8cc0c
#bf6be3
rgb (245, 152, 2)
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
#2c990a
rbg(16, 162, 230)
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(235, 64, 52)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834